|Articles|June 1, 1999

Clinical and Economic Impact of Breast Cancer Treatment and Prevention in High-Risk Women
Volume 5
Issue 6 Suppl

CME Quiz

Articles in this issue

about 27 years ago

Article

The Economics and Challenges of Breast Cancer in a Managed Care Environment

about 27 years ago

Article

Participating Faculty

about 27 years ago

Article

Medical and Economic Impact of Breast Cancer Treatment and Prevention

about 27 years ago

Article

Benefits Foregone: Too Much of the Wrong and Too Little of the Right

about 27 years ago

Article

Breast Cancer: Overview of Current Management Considerations of Economic Impact

about 27 years ago

Article

Breast Cancer Epidemiology: An Overview

about 27 years ago

Article

Overview of Cancer Economics

about 27 years ago

Article

Breast Cancer Stage Cost Analysis in a Managed Care Population

about 27 years ago

Article

The Cost Effectiveness of Tamoxifen in the Prevention of Breast Cancer

about 27 years ago

Article

Question-and-Answer Session

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

ByOnur Baser, PhD, MS,Heidi C. Waters, PhD,Nehir Yapar, BS,Gabriela Samayoa, MD, MPH,Xue Han, PhD,Deborah Freedman, MBA,Lauren Isenman, MPH,Rashmi Patel, MD, PhD

June 12th 2026

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

ByJason Bartock, MD,Adam Green, MD,Raquel Nahra, MD,Amy Bordogna, MD,Amir Davoodi, MD,Jean-Sebastien Rachoin, MD

June 11th 2026

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

ByDana R. Fletcher, PhD,Lisa M. Sandy, MA,Joy Waughtal, MPH,Cole Hoffman, MS,Sylvie Novins-Montague, BA,Patrick Hosokawa, MS,Pamela N. Peterson, MD, MSPH,Larry A. Allen, MD, MPH,Sheana Bull, PhD,P. Michael Ho, MD, PhD

June 10th 2026

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

ByRazanne Oueini, PharmD,Ben Shirley, BS,Christie Teigland, PhD,Melissa Castora-Binkley, PhD, MA,Scott Bilder, PhD,Kiran Sunkari, MS,Lynn Pezzullo, RPh

June 8th 2026

US map with stethoscope | Image Credit: © Andreas Prott - stock.adobe.com

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

ByShifeng Wu, MM

June 5th 2026

CME Quiz

Articles in this issue

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Trending on AJMC

CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes

ATTR-CM Incidence, Prevalence Rose Sharply in the US

Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC

First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention

FDA Approves Palbociclib for HR+, HER2+ Breast Cancer Maintenance

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

CME Quiz

Articles in this issue

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Trending on AJMC

CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes

ATTR-CM Incidence, Prevalence Rose Sharply in the US

Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC

First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention

FDA Approves Palbociclib for HR+, HER2+ Breast Cancer Maintenance